文献速递肾癌与肾肿瘤

「89Zr」girentuximab PET/CT 预测任何肾恶性肿瘤的表现:ZIRCON 试验再分析

Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial.
PubMed 文献 · Eur Urol · 2026-04-22

ZIRCON 3 期试验评估「89Zr」girentuximab(靶向 CAIX 的 PET 示踪剂)检测肾肿块中 ccRCC 的主要终点已达成;本再分析显示该示踪剂也可识别 nccRCC,尤其 CAIX 表达(H score)和 PET 摄取(SUVmax)较高的乳头状 RCC;对任何肾恶性肿瘤的阳性预测值为 98%,灵敏度 82%、特异度 87%。

要点

  • 「89Zr」girentuximab PET/CT 阳性时,任何肾恶性肿瘤的阳性预测值达 98%。
  • 该示踪剂可识别部分 nccRCC,尤其是 CAIX 高表达且 PET 摄取的乳头状 RCC。
  • 对任何肾恶性肿瘤的灵敏度为 82%、特异度为 87%。

核心结论

  • 「89Zr」girentuximab PET/CT 的应用可能超出原发肾肿块中 ccRCC 的检测,并对 nccRCC 的管理有潜在意义。

研究设计与样本

  • ZIRCON 3 期试验的再分析,评估「89Zr」girentuximab PET/CT 预测任何肾恶性肿瘤的表现。

主要发现

  • 再分析显示该示踪剂也可识别 nccRCC,尤其是 CAIX 表达(H score)较高和 PET 摄取(SUVmax)较高的乳头状 RCC。
  • 对任何肾恶性肿瘤的阳性预测值为 98%,灵敏度为 82%,特异度为 87%。

关键数值与推荐

  • 对任何肾恶性肿瘤:阳性预测值 98%,灵敏度 82%,特异度 87%。

临床怎么用

  • 「89Zr」girentuximab PET/CT 阳性时对任何肾恶性肿瘤的阳性预测值高,可辅助肾肿块恶性判断。
  • 对 nccRCC(尤其乳头状 RCC)的识别可能影响其管理决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carbonic anhydrase IX (CAIX) is a cell surface protein expressed in over 90% of clear cell renal cell carcinoma (ccRCC), driven by hypoxia or Von-Hippel Lindau (VHL) loss. The phase 3 ZIRCON trial evaluated [89Zr]girentuximab, a CAIX-targeted positron emission tomography (PET) radiotracer, and met its primary endpoint for the accurate detection of ccRCC in patients with renal masses. Many aggressive forms of non-ccRCC (nccRCC) can express CAIX, which is linked to a hypoxic state. A reanalysis of the trial was performed demonstrating the tracer also identified nccRCC, particularly in forms of papillary RCC (pRCC) with higher CAIX expression (H score) and PET avidity (SUVmax). The positive predictive value for any renal malignancy was 98%, with sensitivity/specificity of 82% and 87%, respectively. This suggests [89Zr]girentuximab has applications beyond the detection of ccRCC in primary renal masses and may have implications to management of nccRCC. PATIENT SUMMARY: The ZIRCON phase 3 trial used an imaging agent ([89Zr]girentuximab) with a primary focus to detect the most common kidney cancer, clear cell renal cell carcinoma. Other forms of kidney cancer can express the marker that the imaging agent can identify. The additional analysis showed that when positive, 98% of cases were correctly identified as any form of cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kaba A, Kanabur P, Calais J, et al. Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial. Eur Urol. 2026. PMID: 42025513. doi:10.1016/j.eururo.2026.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。